Article Figures & Data
Figures
- Fig. 1.
A, pSTAT3tyr705/STAT3 double immunostaining of melanoma cells in the lymph node metastases. Formaldehyde-fixed, paraffin-embedded tissues of nine cases with adequate biopsy samples pre-HDI and post-HDI therapy were available for evaluation of pSTAT3tyr705 and STAT3. Only seven cases had adequate biopsy samples available before and after HDI for analysis of tumor and eight cases for analysis of lymphocytes. Columns, mean; bars, SE. B, pSTAT3tyr705/STAT3 double immunostaining of lymphocytes in the lymph node metastases. Similar phenomena were observed among lymphocytes as in tumor cells. Columns, mean; bars, SE.
- Fig. 2.
A to C, pSTAT1tyr701 and pSTAT3tyr705 double immunostains of nodal melanoma cells. Snap-frozen tissues (total of 12 cases) pre-HDI and post-HDI therapy were stained for pSTAT1tyr701 or pSTAT3tyr705. Columns, mean; bars, SE. D to F, pSTAT1tyr701 and pSTAT3tyr705 double immunostains of nodal lymphocytes. Similar phenomena were observed among lymphocytes as in tumor cells. Points, mean; bars, SE.
- Fig. 3.
A, pSTAT1/pSTAT3 ratio in melanoma cells versus overall survival indicates that patients with higher pSTAT1/pSTAT3 ratios in pretreatment tumor samples have prolonged overall survival (P = 0.032). B, pSTAT1/pSTAT3 ratio in lymphocytes versus overall survival does not show significant correlation (P = 0.226). Low, patients whose pSTAT1/pSTAT3 ratio was at or below the median value; high, patients whose pSTAT1/pSTAT3 ratio was above the median value.
- Fig. 4.
High-dose IFNα2b up-regulates TAP2 in tumor cells and immune cells. Magnification, ×20. Red, TAP2; blue, counterstain. A1 to A5, pretreatment sections; B1 to B5, posttreatment sections; the red color (representing TAP2) is strongly increased in intensity and percentage of cells observed. Small yellowish brown particles, melanin. Black arrows, lymphoid cells.
Tables
- Table 1.
Patient clinical information
Patient no. Age (y) Sex Disease status Disease stage at original diagnosis HDI completed Response Duration of disease-free interval (mo) Current status Clinical Pathologic 801 50 M I T4aN2b(cl) 1/3DR CR RMiD 32 Deceased 803 42 M I T4bNx Yes NR RMaD 6 Deceased 804 65 F R T3aN0(s) Yes NR RMaD 1 Deceased 805 41 M R T1bN0(cl) Yes PR RMiD 49 NED 806 56 M R T3a(al)N0(cl) Yes NR CR 34 MET 807 66 F R T3bN0(s) Yes NR RMaD 32 NED 809 56 F I T4bN3(cl) Yes NR RMaD 6 Deceased 810 60 M I T4bN2b(cl) Yes NR RMaD 6 Deceased 811 72 F R T3aN0(cl) Yes PR RMaD 30 NED 812 76 M R TxN0(s) Yes PR RMaD 15 MET 814 57 F I TxN3(cl) 1/3DR PR RMaD 4 Deceased 817 62 M IP TxN3(cl) 1/3DR PR RMaD 10 NED NOTE: Adapted from ref. 18.
Abbreviations: M, male; F, female; I, initial presentation; R, regional lymph node recurrence; IP, isolated palpable nodal metastases arising from an unknown primary; cl, nodal staging based on clinical exam; s, nodal staging based on sentinel lymph node mapping and pathologic interpretation; DR, dose reduction; CR, complete response; PR, partial response; NR, no response; RMiD, residual microscopic disease; RMaD, residual macroscopic disease; NED, no evidence of disease; MET, metastatic disease.
Volume 13, Issue 5
